Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I
Hematology Disease Topics & Pathways:
Research, Translational Research
Method. To find new therapeutics active in resistant AML, we collected clinical data and bone marrow or peripheral blasts at AML diagnosis in a prospective biobanking clinical trial named HEMATO-BIO-IPC 2013-015 (NCT02320656, PI: Prof. N Vey), between 2014 and 2019. We performed targeted DNA sequencing using a NGS panel of recurrently mutated AML genes and ex vivo drug sensitivity/resistance profiling (DSRP).
Results. Taking the first 108 AML analyzed samples, we identified that 17 (15.7%) were resistant to NAV (NAV-R), taking a Z score >0.75 as a threshold. The patient median age was 62.5 yo, median leukocyte count, platelet count, percentage of blasts were 29.7 G/L (ranges, 1.1-86.3), 67 G/L (ranges, 18-163) and 72% (ranges, 21-93), respectively. Twelve AML were classified as FAB4 (n=6) and FAB5 (n=6). Cytogenetics was normal in 9 cases. NPM1 mutation was found in 6 and FLT3-ITD in 4 cases. Signaling mutations, including NRAS, KRAS and PTPN11 mutations, were found in 3, 2 and 2 cases, respectively. No samples were found with KIT mutations and only 2 samples had a TP53 mutation. We noticed a strong anticorrelation between NAV-R and sensitivity to most of the tested kinase inhibitors, including the Pi3K-inh BKM120 (Buparlisib) and Idelalisib, the JAK2-inh Ruxolitinib, the MEK-inh Trametinib, the mTOR-inh Temsirolimus, the FLT3-inh Quizartinib, and the BCR-ABL-inh Imatinib and Dasatinib (DASA). On the other hand, we did not observe any anticorrelation with the EGFR-inh erlotinib nor gefitinib. Amongst the most active kinase inhibitors, DASA had the lowest median IC50 (Z-score=0,01511). As DASA has already been used in clinical settings in AML, we chose DASA for further tests. We first confirmed the anticorrelation between DASA and the BCL2/BCLxL-inh ABT797 in the BEAT-AML cohort. As NAV and ABT797 are both known BCL2/BCLxL-inh, we hypothesized that blasts sensitive do DASA (DASA-S) were in fact dependent on MCL1. Indeed, western blot (WB) analysis showed higher MCL1 and proapoptotic BIM protein levels. To link a possible dependence of DASA-S blasts to MCL1, we performed BH3 profiling in 25 AML samples. We confirmed that DASA-S samples had a strong MCL1 dependency as shown by a dose-dependent mitochondrial membrane depolarization using MS1 peptide and a high MS1/BAD ratio. We next hypothesized that DASA was targeting MCL1 through an indirect manner. We performed a WB of MCL1 using AML cell line K562 and HL60, and observed a dose dependent decrease in MCL1 protein levels upon DASA treatment while BCL2 expression was not altered. Collectively, these results suggest that DASA could be a potential MCL1 indirect inhibitor that could be used in the clinical settings to treat VEN-R AML. To prove this hypothesis, we designed a phase II clinical trial named VEN-R DASA-IPC 2022 067 (EUCT 2023-505846-24-00) that is currently enrolling patients failing a minimum of two VEN-AZA cycles.
Conclusion. DASA may be efficient in targeting VEN-R by inhibiting MCL1. Preclinical studies based on the AML collections HEMATIO-BIO allowed us to ask clinical questions that can be addressed in early-phase clinical trial.
Disclosures: Garciaz: Janssen: Consultancy, Honoraria; Imcheck Therapeutics: Consultancy; Servier: Consultancy, Honoraria; Sanofi: Consultancy, Other: travel grant; Abbvie: Consultancy, Honoraria, Other: Travel grant; BMS: Consultancy.
See more of: Oral and Poster Abstracts